The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: A systematic review

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

OBJECTIVES: Endoscopic eradication therapy is used to treat mucosal neoplasms in Barrett's esophagus, but cannot cure cancers that have metastasized to lymph nodes. The risk of such metastases has been proposed as a reason to consider esophagectomy rather than endoscopic therapy for esophageal mucosal neoplasia. The objective of our study was to determine the frequency of lymph-node metastases in patients with high-grade dysplasia (HGD) and intramucosal carcinoma in Barrett's esophagus. METHODS: We performed a systematic review using the PRISMA guidelines to identify studies that included patients who had esophagectomy for HGD or intramucosal carcinoma in Barrett's esophagus, and that reported final pathology results after examination of esophagectomy specimens. RESULTS: We identified 70 relevant reports that included 1,874 patients who had esophagectomy performed for HGD or intramucosal carcinoma in Barrett's esophagus. Lymph-node metastases were found in 26 patients (1.39%, 95% CI 0.86-1.92). No metastases were found in the 524 patients who had a final pathology diagnosis of HGD, whereas 26 (1.93%, 95% CI 1.19-2.66%) of the 1,350 patients with a final pathology diagnosis of intramucosal carcinoma had positive lymph nodes. CONCLUSIONS: The risk of unexpected lymph-node metastases for patients with mucosal neoplasms in Barrett's esophagus is in the range of 1-2%. Esophagectomy has a mortality rate that often exceeds 2%, with substantial morbidity and no guarantee of curing metastatic disease. Therefore, the risk of lymph-node metastases alone does not warrant the choice of esophagectomy over endoscopic therapy for HGD and intramucosal carcinoma in Barrett's esophagus.

Original languageEnglish (US)
Pages (from-to)850-862
Number of pages13
JournalAmerican Journal of Gastroenterology
Volume107
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Barrett Esophagus
Esophagectomy
Lymph Nodes
Neoplasm Metastasis
Carcinoma
Pathology
Neoplasms
Therapeutics
Guidelines
Morbidity
Mortality

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{b41f344e5d694429a160938e4100bd1a,
title = "The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: A systematic review",
abstract = "OBJECTIVES: Endoscopic eradication therapy is used to treat mucosal neoplasms in Barrett's esophagus, but cannot cure cancers that have metastasized to lymph nodes. The risk of such metastases has been proposed as a reason to consider esophagectomy rather than endoscopic therapy for esophageal mucosal neoplasia. The objective of our study was to determine the frequency of lymph-node metastases in patients with high-grade dysplasia (HGD) and intramucosal carcinoma in Barrett's esophagus. METHODS: We performed a systematic review using the PRISMA guidelines to identify studies that included patients who had esophagectomy for HGD or intramucosal carcinoma in Barrett's esophagus, and that reported final pathology results after examination of esophagectomy specimens. RESULTS: We identified 70 relevant reports that included 1,874 patients who had esophagectomy performed for HGD or intramucosal carcinoma in Barrett's esophagus. Lymph-node metastases were found in 26 patients (1.39{\%}, 95{\%} CI 0.86-1.92). No metastases were found in the 524 patients who had a final pathology diagnosis of HGD, whereas 26 (1.93{\%}, 95{\%} CI 1.19-2.66{\%}) of the 1,350 patients with a final pathology diagnosis of intramucosal carcinoma had positive lymph nodes. CONCLUSIONS: The risk of unexpected lymph-node metastases for patients with mucosal neoplasms in Barrett's esophagus is in the range of 1-2{\%}. Esophagectomy has a mortality rate that often exceeds 2{\%}, with substantial morbidity and no guarantee of curing metastatic disease. Therefore, the risk of lymph-node metastases alone does not warrant the choice of esophagectomy over endoscopic therapy for HGD and intramucosal carcinoma in Barrett's esophagus.",
author = "Dunbar, {Kerry B.} and Spechler, {Stuart Jon}",
year = "2012",
month = "6",
doi = "10.1038/ajg.2012.78",
language = "English (US)",
volume = "107",
pages = "850--862",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus

T2 - A systematic review

AU - Dunbar, Kerry B.

AU - Spechler, Stuart Jon

PY - 2012/6

Y1 - 2012/6

N2 - OBJECTIVES: Endoscopic eradication therapy is used to treat mucosal neoplasms in Barrett's esophagus, but cannot cure cancers that have metastasized to lymph nodes. The risk of such metastases has been proposed as a reason to consider esophagectomy rather than endoscopic therapy for esophageal mucosal neoplasia. The objective of our study was to determine the frequency of lymph-node metastases in patients with high-grade dysplasia (HGD) and intramucosal carcinoma in Barrett's esophagus. METHODS: We performed a systematic review using the PRISMA guidelines to identify studies that included patients who had esophagectomy for HGD or intramucosal carcinoma in Barrett's esophagus, and that reported final pathology results after examination of esophagectomy specimens. RESULTS: We identified 70 relevant reports that included 1,874 patients who had esophagectomy performed for HGD or intramucosal carcinoma in Barrett's esophagus. Lymph-node metastases were found in 26 patients (1.39%, 95% CI 0.86-1.92). No metastases were found in the 524 patients who had a final pathology diagnosis of HGD, whereas 26 (1.93%, 95% CI 1.19-2.66%) of the 1,350 patients with a final pathology diagnosis of intramucosal carcinoma had positive lymph nodes. CONCLUSIONS: The risk of unexpected lymph-node metastases for patients with mucosal neoplasms in Barrett's esophagus is in the range of 1-2%. Esophagectomy has a mortality rate that often exceeds 2%, with substantial morbidity and no guarantee of curing metastatic disease. Therefore, the risk of lymph-node metastases alone does not warrant the choice of esophagectomy over endoscopic therapy for HGD and intramucosal carcinoma in Barrett's esophagus.

AB - OBJECTIVES: Endoscopic eradication therapy is used to treat mucosal neoplasms in Barrett's esophagus, but cannot cure cancers that have metastasized to lymph nodes. The risk of such metastases has been proposed as a reason to consider esophagectomy rather than endoscopic therapy for esophageal mucosal neoplasia. The objective of our study was to determine the frequency of lymph-node metastases in patients with high-grade dysplasia (HGD) and intramucosal carcinoma in Barrett's esophagus. METHODS: We performed a systematic review using the PRISMA guidelines to identify studies that included patients who had esophagectomy for HGD or intramucosal carcinoma in Barrett's esophagus, and that reported final pathology results after examination of esophagectomy specimens. RESULTS: We identified 70 relevant reports that included 1,874 patients who had esophagectomy performed for HGD or intramucosal carcinoma in Barrett's esophagus. Lymph-node metastases were found in 26 patients (1.39%, 95% CI 0.86-1.92). No metastases were found in the 524 patients who had a final pathology diagnosis of HGD, whereas 26 (1.93%, 95% CI 1.19-2.66%) of the 1,350 patients with a final pathology diagnosis of intramucosal carcinoma had positive lymph nodes. CONCLUSIONS: The risk of unexpected lymph-node metastases for patients with mucosal neoplasms in Barrett's esophagus is in the range of 1-2%. Esophagectomy has a mortality rate that often exceeds 2%, with substantial morbidity and no guarantee of curing metastatic disease. Therefore, the risk of lymph-node metastases alone does not warrant the choice of esophagectomy over endoscopic therapy for HGD and intramucosal carcinoma in Barrett's esophagus.

UR - http://www.scopus.com/inward/record.url?scp=84861888970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861888970&partnerID=8YFLogxK

U2 - 10.1038/ajg.2012.78

DO - 10.1038/ajg.2012.78

M3 - Article

C2 - 22488081

AN - SCOPUS:84861888970

VL - 107

SP - 850

EP - 862

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 6

ER -